论文部分内容阅读
观察艾塞那肽对2型糖尿病患者血糖控制情况。将2010年7月～12月间应用艾塞那肽的15例2型糖尿病患者进行一般资料分析:包括年龄、糖尿病病程、空腹血糖、餐后血糖、糖化血红蛋白,甘油三酯、胆固醇、就诊时降糖药物应用药统计。对患者进行艾塞那肽5μg一日2次早晚餐前1 h皮下注射后,观察用药前后空腹血糖及餐后2 h血糖变化。结果显示用艾塞那肽后空腹血糖及餐后血糖均较用药前下降,艾塞那肽降低餐后血糖较空腹血糖程度高。艾塞那肽可短时间内有效降低空腹及餐后血糖,降低餐后血糖较空腹血糖效果好。
Observed exenatide in patients with type 2 diabetes glycemic control. Fifty-two patients with exacerbation of exenatide from July to December 2010 were analyzed for general data including age, duration of diabetes, fasting blood glucose, postprandial blood glucose, glycosylated hemoglobin, triglycerides, cholesterol, Hypoglycemic drug application drug statistics. The patients were given exenatide 5μg 2 times a day before and after 1h subcutaneous injection, observed before and after fasting blood glucose and postprandial 2h blood glucose changes. The results showed that fasting blood glucose and postprandial blood glucose decreased with exenatide compared with pre-treatment, and that exenatide reduced postprandial blood glucose more than fasting blood glucose. Exenatide can effectively reduce fasting and postprandial blood glucose within a short period of time, reducing postprandial blood glucose better than fasting blood glucose.